Germany-based Axplora says it has invested €50 million ($51.8 million) in its Mourenx site in Southwest France. Axplora specializes in large-scale API industrial chemistry and chromatography with a focus on cardiovascular and metabolic diseases.
By upgrading Mourenx’s infrastructure and capabilities, Axplora expects to strengthen its position in peptide purification in a biologics environment and support the development of next-generation therapies, including GLP-1 drugs that target diabetes and obesity, which represent some of society’s most urgent health challenges, according to Arul Ramadurai, chief commercial officer of Axplora.
“GLP-1 therapies represent a paradigm shift in medicine, offering targeted therapies for complex diseases with unprecedented efficacy and tolerability,” continued Ramadurai.
Construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026. Axplora operates nine API manufacturing sites across Europe and India, with the goal of providing multi-site capacity to partners worldwide.
